NEW YORK (360Dx) – Researchers at the Swiss Federal Institute of Technology (SFIT) in Lausanne are using C-reactive protein as a biomarker to develop an assay that they believe could become part of a commercial test applied at the point of care to detect cardiac conditions.

The assay requires small sample quantities, and it could be inexpensively screen-printed from carbon, a cheap and plentiful material, Madasamy Thangamuthu, one of its developers and a researcher in the nanophotonics and metrology lab at Swiss Federal, said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.